猪源大肠杆菌O157:H7鞭毛蛋白抗原表位分析及验证

利用生物信息学分析大肠杆菌O157:H7鞭毛蛋白FliC的二级结构及亲水性、抗原指数、柔性区域和表面可能性等指数,预测大肠杆菌O157:H7鞭毛蛋白FliC的潜在B细胞抗原表位,为其致病性研究提供理论基础。利用DNAStar软件Protean程序中Garnier-Robson方法和Chou-Fasman方法分析鞭毛蛋白FliC的α-螺旋、β-折叠、转角区域和卷曲区域,通过Kyte-Doolittle方法、Karplus-Schulz方法、Emini方法和Jameson-Wolf方法分析鞭毛蛋白FliC的亲水性、柔性区域、表面可能性和抗原指数。综合分析得出鞭毛蛋白FliC 63-74、236-247、338-349、460-471、542-553位氨基酸序列为潜在的B细胞优势抗原表位。化学合成法合成优势抗原表位338-349和460-471肽段,免疫BALB/c小鼠3次后,采用ELISA方法验证抗体水平。ELISA结果显示,338-349、460-471肽段具有很强的抗原性,能引起BALB/c小鼠产生高滴度的抗体。     

大肠杆菌O157∶H7单克隆抗体胶体金免疫层析检测试纸条的研制

用E.coliO157∶H7菌体免疫BALB/c鼠,制备免疫脾细胞,与SP2/0骨髓瘤细胞融合,获得了16株分泌单克隆抗体（mAb）的杂交瘤细胞株。其中,1D3、2E7和2H7三株为O157∶H7特异单克隆抗体,Ig亚类分别为IgMκ、IgG2bκ和IgG2bκ,腹水抗体ELISA效价分别为103、105和106。用纯化的单克隆抗体2E7标记胶体金,制备金标抗体玻璃纤维素膜;将纯化的2H7和羊抗鼠IgG分别作为检测和对照捕捉抗体包被于硝酸纤维素膜（NC）上;组装成双抗夹心法O157∶H7胶体金免疫层析检测试纸条。用该试纸条可特异检测O157∶H7,敏感度为106CFU/mL,与相同单克隆抗体2H7和2E7建立的O157∶H7夹心ELISA检测方法的敏感度相当,试纸条简便快速,在1~5 min内可得出检测结果,便于O157∶H7的临床快速诊断与现场检测样品的快速筛查。     

口蹄疫疫苗非抗原蛋白对146S抗原免疫效果的影响

为探究非抗原蛋白对口蹄疫病毒A型(FMDV-A) 146S抗原免疫效果的影响,本研究以小鼠和猪为试验动物,分别制备5组小鼠注射用样品:A组(3μg 146S抗原)、B组(3μg 146S抗原+25μg非抗原蛋白)、C组(3μg 146S抗原+50μg非抗原蛋白)、D组(3μg 146S抗原+100μg非抗原蛋白)及E组(空白对照,PBS);同时制备4组猪注射用样品:A组(18μg 146S抗原)、B组(18μg 146S抗原+400μg非抗原蛋白)、C(18μg 146S抗原+4 000μg非抗原蛋白)及D组(空白对照,PBS)。免疫接种试验动物后,通过淋巴细胞增殖试验及实时荧光定量PCR评价比较不同疫苗样品组小鼠产生的细胞免疫应答水平,同时通过液相阻断ELISA方法检测、评价各试验组动物(小鼠和猪)产生的体液免疫应答水平。小鼠试验结果显示,在免疫后3个检测时间点内,4个试验组中C组的平均抗体水平最高,平均抗体效价分别为4.13、5.83和5.50,而D组的抗体水平最低,平均抗体效价分别为3.46、5.16和4.46;C组细胞增殖能力及Th-1型细胞因子IL-6、IFN-β和TNF-αmRNA表达量均高于其他组。猪试验结果显示,A组和B组间平均抗体水平差异不显著(P>0.05),但A组和B组的平均抗体效价均极显著高于C组(P<0.01)。综合上述结果表明,一定范围内少量非抗原蛋白对FMDV-A 146S抗原的免疫效果没有影响,而高浓度的非抗原蛋白则抑制FMDV-A 146S抗原的免疫效果。     

出血性大肠杆菌O157 Eae-Stx1/2B融合蛋白的免疫学特性

为了研究重构融合蛋白Eae-Stx1/2B免疫特性及对出血性大肠杆菌感染的免疫保护作用,进行了细胞粘附抑制试验和免疫保护试验。结果证明Eae-Stx1/2B融合蛋白免疫血清在体外能降低出血性大肠杆菌对HEp-2细胞的粘附作用,这一特性在出血性大肠杆菌疫苗设计中具有重要价值。以纯化的融合蛋白Eae-Stx1/2B为抗原对小鼠进行腹腔注射免疫和滴鼻免疫,ELISA检测结果显示,2次免疫后7 d,免疫组抗Eae-Stx1/2B融合蛋白和抗出血性大肠杆菌O157血清IgG抗体显著高于未免疫组;用出血性大肠杆菌O157强毒株EDL933攻击免疫小鼠,免疫组小鼠排菌时间显著缩短,免疫组小鼠存活率均高于未免疫组,免疫组小鼠体质量恢复增长较快。上述试验结果表明,Eae-Stx1/2B融合蛋白对出血性大肠杆菌感染有保护作用。     

重组鸡IL-2对禽流感灭活苗免疫增强作用试验

使用重组鸡白介素-2作为免疫佐剂,检测chIL-2对禽流感病毒H9亚型灭活疫苗的免疫增强作用。将1日龄的AA肉雏鸡,随机分为7组,每组10只,采用胸部肌肉注射方式进行免疫,对照组仅接种H9亚型禽流感灭活疫苗,试验组分别同时接种H9亚型禽流感灭活疫苗O．5mL和不同剂量（0．01mg-1mg）的鸡IL-2。每7d静脉采血,采用血凝和血凝抑制方法检测机体中抗体水平变化情况。结果表明,接种重组鸡IL-2的试验组动物能在2月内保持高抗体水平,且在免疫后第10周,其平均抗体水平仍高于疫苗对照组3．6个～4．5个滴度,表明了重组鸡IL-2蛋白对H9亚型禽流感灭活疫苗具有免疫增强作用。     

Isotype-specific antibody responses against Escherichia coli O157:H7 locus of enterocyte effacement proteins in adult beef cattle following experimental infection

Escherichia coli O157:H7 is an important food-borne pathogen and cause of hemorrhagic colitis and hemolytic uremic syndrome in humans. Cattle are an important reservoir of E. coli O157:H7, in which the organism colonizes the intestinal tract and is shed in the feces. Vaccination of cattle has significant potential as a pre-harvest intervention strategy for E. coli O157:H7; however, basic information about the bovine immune responses to important bacterial colonization factors resulting from infection has not been reported. The serum and fecal IgG and IgA antibody responses of adult cattle to E. coli O157:H7 intimin, translocated intimin receptor (Tir), E. coli-secreted proteins (Esp)A, EspB and O157 lipopolysaccharide (LPS) in response to infection were determined. All animals were seropositive for all five antigens prior to inoculation, with antibody titers to EspB and O157 LPS significantly higher (P<0.05) than those to Tir, intimin and EspA. After inoculation, the cattle became colonized and developed significant increases in their serum antibody titers to intimin, Tir, EspB, EspA and O157 LPS (P<0.05); however, by 42 days post-inoculation the titers to all except EspB were on the decline. In contrast, pre- and post-inoculation fecal IgG and IgA antibodies to these same antigens were not detected (<1:5). These results indicate that cattle respond serologically to E. coli O157:H7 type III secreted proteins, intimin and O157 LPS during the course of infection and the response is correlated with the extent of fecal shedding.     

Fusion of C3d with hemagglutinin enhances protective immunity against swine influenza virus

H1N1 and H3N2 are the dominant subtypes causing swine influenza in China and other countries. It is important to develop effective vaccines against both H1N1 and H3N2 subtypes of swine influenza virus (SIV). We examined the effects of a DNA vaccine expressing an influenza HA fused to three copies of murine complement C3d in mice. Plasmids encoding soluble HA (sHA), complete HA (tmHA), or a soluble fused form of HA (sHA-mC3d3) were constructed from the H3N2 subtype of SIV. The immune response was monitored by an enzyme-linked immunosorbent assay (ELISA), hemagglutination inhibition (HI) assays, and virus neutralization tests. Analysis of antibody titers indicated that immunization with HA-mC3d3 resulted in higher titers of anti-HA antibodies and higher antibody affinities, compared with serum from mice immunized with sHA or tmHA. Furthermore, the C3d fusion increased the Th2-biased immune response, by inducing IL-4 production. Splenocytes from mice immunized with sHA-mC3d3 produced about three-fold more IL-4 than did splenocytes from mice immunized with sHA or tmHA. Seven days post-challenge with homologous virus (H3N2), no virus was isolated from the mice immunized with HA-expressing plasmids. However, 10 days post-challenge with heterologous virus (H1N1), only mice immunized with sHA-mC3d3 had no virus or microscopic lesions in the kidneys and cerebrum. In conclusion, C3d enhanced antibody responses to hemagglutinin and protective immunity against SIV of different subtypes.     

猪流行性腹泻病毒S2基因B细胞表位的筛选及其单克隆抗体的制备与鉴定

目的 应用生物学软件与单克隆抗体技术相结合的方法鉴定PEDV S2基因B细胞表位肽。方法 利用CLC Sequence viewer 6.8软件及在线数据库IEDB筛选出PEDV S2基因B细胞表位,并人工合成表位肽。将表位肽与钥孔血蓝蛋白（KLH）耦联后作为抗原,免疫雌性BALB/c小鼠,通过ELISA法筛选出抗体效价较高的小鼠进行1次加强免疫,3 d后取脾脏制备脾细胞悬液进行细胞融合。经HAT选择培养基培养筛选有效杂交瘤细胞,采用ELISA法筛选阳性克隆继续进行扩大培养。将部分阳性杂交瘤细胞进行小鼠腹腔注射,并收集腹水。通过ELISA方法分别检测小鼠腹水和单克隆细胞株培养上清液抗体效价,确定最高效价作为后备细胞株。结果 筛选出B细胞表位肽序列为:MQYVYTPTYYML;免疫多肽抗原后融合前血清抗体效价达到1:2 000;BALB/c小鼠腹水及单克隆细胞株培养物上清液ELISA检测结果显示抗体效价达到1:4 000。结论 筛选出了PEDV S2基因B细胞表位,为PEDV表位肽疫苗载体构建研究提供参考。     

小鼠对温和气单胞菌口服缓释微球疫苗的免疫应答

采用中华鳖温和气单胞菌(Aeromonas sobria,As)Z-1株灭活全菌液,以生物降解性高分子材料为载体,制成微球疫苗,口服免疫ICR小鼠,测定了血清中凝集抗体效价、血液中单核-巨噬细胞的吞噬活性以及对活菌攻击的免疫保护力.结果显示小鼠微球疫苗口服免疫后第4周,血清中凝集抗体效价和血液中单核-巨噬细胞的吞噬指数均可达到与灭活菌液注射组相当的水平(P＞0.05),明显高于灭活菌液口服组(P＜0.01);免疫后第7～12周,微球疫苗口服组血清凝集抗体效价显著高于灭活菌液注射组(P＜0.05);微球疫苗口服组和灭活菌液注射组的免疫保护力均为87.5%,而灭活菌液口服组不能提供有效的保护,与对照组死亡率相同(100%).结论认为,中华鳖气单胞菌口服微球疫苗具有缓释作用;以可生物降解的微球作为中华鳖气单胞菌口服疫苗的载体系统具有潜在的优势.     

Prokaryotic Expression and Antigenicity Analysis of Porcine Japenese Encephalitis Virus Envelope Protein Domain Ⅲ

In order to analyze the antigenicity of porcine Japanese encephalitis virus (JEV) E protein domain Ⅲ, which was expressed by pET-28a vector with His-tag and purified through Ni-NTA, the BALB/c mice were immunized with the purified protein.We identified the antigenicity of domain Ⅲ of E protein and the anti-mice and anti-porcine JEV E Ⅲ protein specific antibody titers by SDS-PAGE, Western blotting, indirect ELISA and IFA.SDS-PAGE results showed the expressed target protein existed mainly in the form of inclusion body.Western blotting, ELISA test results showed that the protein had good reactivity with anti-serum.The mice immunized with the purified JEV E Ⅲ protein generated 1×10⁵ anti-JEV E Ⅲ protein specific antibody titers by ELISA, and the porcine immunized with the porcine JEV generated 5.1×10⁴ anti-JEV specific antibody titers.The IFA results showed that JEV E Ⅲ protein anti-serum could identify JEV antigen.The above results showed that the recombinant JEV E Ⅲ had good antigenicity.These results provided important basis for development of diagnostic antigen for JEV.     

猪乙型脑炎病毒E蛋白结构域Ⅲ原核表达和抗原性分析

为分析猪乙型脑炎病毒(JEV)E蛋白Ⅲ结构域的抗原性,本研究克隆了JEV疫苗株SA14-14-2的E蛋白结构域Ⅲ,并通过pET-28a载体进行融合表达和纯化。用纯化后蛋白作为免疫原,免疫8周龄BALB/c小鼠,通过SDS-PAGE、Western blotting、间接ELISA及间接免疫荧光方法(IFA)检测小鼠及猪抗体滴度,验证E蛋白结构域Ⅲ的抗原性。SDS-PAGE结果表明融合蛋白以包涵体形式表达;Western blotting、间接ELISA检测结果表明表达产物具有良好的抗原性;纯化的蛋白免疫BALB/c小鼠ELISA方法检测特异性抗体滴度可达1×10⁵;猪JEV阳性血清ELISA抗体滴度可达5.1×10⁴;IFA结果表明JEV E Ⅲ蛋白产生的抗血清能很好的识别乙型脑炎病毒抗原。以上结果表明,表达、纯化的重组JEV E Ⅲ蛋白具有良好的抗原性。本试验结果为建立以E蛋白结构域为抗原的诊断方法提供了重要依据。     

磷酸钙作为O型口蹄疫多肽疫苗佐剂的研究

为了探索磷酸钙(calcium phosphate,CaP)作为多肽疫苗佐剂的可行性,本研究以O型口蹄疫多肽疫苗为抗原,采用共沉淀法制备CaP-多肽复合物,测定包封率。将制备好的疫苗,分别在0、14、28 d腹腔注射免疫Wistar大鼠,尾静脉采血检测口蹄疫抗体水平。结果显示,CaP可包裹一定量的O型口蹄疫多肽,包封率达到50%,免疫大鼠后油佐剂组抗体效价在14 d达到26,42 d增至210并可维持35~42 d;CaP组在21 d后陆续产生抗体,抗体水平较油佐剂低,为27~28。结果表明,CaP作为佐剂相对游离多肽可以提高O型口蹄疫多肽疫苗免疫效果,但抗体水平相对油佐剂低。     

H9亚型禽流感病毒流行毒株交叉免疫攻毒保护试验

采用1998-2009年在河北、河南及山东分离的3株禽流感H9亚型流行毒株,分别制备灭活疫苗,免疫SPF鸡,免疫后21 d,采血测定HI抗体,然后用从上述3个地区及北京分离的共5株禽流感H9亚型流行毒株进行攻击,观察不同时期及地点分离的H9亚型流行毒株的交叉免疫攻毒保护效果。结果显示,用不同时期及地点的3个分离毒株所制备出的灭活疫苗免疫鸡后,各免疫组试验鸡H9亚型禽流感的HI抗体效价均明显上升,不同毒株灭活疫苗所诱导产生的HI抗体效价存在着不同程度的差异,用同源毒株作为抗原测定免疫组鸡的血清样品,可获得较高的HI抗体效价。攻毒试验结果证明,对不同时期及地点分离的禽流感H9亚型流行毒株间产生了较好的交叉保护力。用1998年分离的WD98株制备出的灭活疫苗对目前的流行毒株仍具有较好的保护效力。     

重组SEA增强H5亚型禽流感灭活疫苗对肉鸡的免疫效果研究

为评价重组葡萄球菌肠毒素A(rSEA)对H5亚型禽流感病毒(AIV)灭活疫苗免疫效果的影响,本研究以原核表达的rSEA为免疫增强剂,制备成含有rSEA高(167 μg/0.5 mL)、低(16.7 μg/0.5 mL)两种剂量的AIV油乳剂灭活苗,分别免疫7d龄肉鸡,通过检测免疫鸡AIV HI抗体滴度及外周血CD4+/CD8+值评价其免疫效果.HI 抗体检测结果显示,免疫后2周高剂量组HI抗体平均滴度为5.6 log2,低剂量组为4.2 log2,而无rSEA疫苗对照组为2.9 log2(p＜0.01);同时在免疫后前4周,rSEA免疫组的HI抗体平均滴度及峰值与对照组相比均差异显著(p＜0.05).T淋巴细胞亚群检测结果显示,肉鸡免疫高剂量rSEA的灭活苗后,其外周血CD4+百分含量及CD4+/CD8+值均显著高于对照组(p＜0.05).上述结果表明,rSEA作为AIV灭活苗免疫增强剂,能够快速诱导较高的HI抗体滴度,同时也可增强细胞免疫反应,有效缩短免疫空白期,使肉鸡短时间内产生较强的免疫应答反应.     

猪流感病毒多表位抗原的小鼠黏膜免疫试验

为探讨经黏膜途径免疫接种猪流感病毒(SIV)多肽疫苗的可行性,选择STV主要结构蛋白血凝素(HA)的T、B抗原表位,将多个表位片段串联,定向克隆到原核表达载体pET-30a(+)中,对串联表达的重组猪流感病毒蛋白SIV-ep1、SW-ep2、SIV-el2进行了小鼠免疫试验。重组蛋白以包涵体形式表达,经洗涤定量后,采用灌胃途径免疫6周龄KM小鼠,检测免疫小鼠抗体及细胞免疫水平。结果发现三免后各免疫组血清IgG抗体与PBS对照组差异极显著(P<0.01);黏膜分泌型IgA抗体,所有免疫蛋白组与PBS组差异均极显著(P<0.01);细胞免疫检测,所有免疫组小鼠外周血T淋巴细胞增殖明显;猪流感病毒血凝抗体检测,SIV-ep1免疫组、SIV-ep2免疫组、SIV-ep1与LT蛋白免疫组抗SIVH1N1亚型HI效价达1:1024,SIV-el2蛋白免疫组HI效价达1:512。结果表明,猪流感病毒重组多表位抗原灌胃免疫小鼠,能产生理想的黏膜免疫抗体和血清抗体。     

羊口蹄疫O型-亚洲1型二价灭活疫苗免疫后O型抗体水平的检测

为了探讨口蹄疫O型-亚洲1型二价灭活苗免疫接种羊后产生的O型抗体效价,采用不同免疫剂量和不同免疫时间免疫接种羊,应用正向间接血凝试验(IHA),检测其抗体消长规律.结果表明,羔羊母源抗体水平及维持时间与母羊抗体水平呈正相关,有效保护抗体能维持70 d左右;首免每只1 mL、2 mL同时免疫的4组间免疫抗体水平经方差分析差异不显著,首免不能产生有效的保护抗体水平;二免2 mL、2.5 mL不同时间免疫的4组,首免后15 d与首免后28 d进行二免产生的抗体经t检验差异极显著(P<0.01),首免后28 d二免的不同剂量组经方差分析差异不显著,有效抗体能维持约170 d,首免后15 d二免的免疫抗体水平最低;每只三免2 mL、3 mL的2个剂量组产生的有效抗体均能维持180 d,两组抗体经t检验差异不显著(P>0.05).     

H9N2亚型禽流感病毒中和单克隆抗体的制备与应用

为建立H9N2亚型禽流感病毒（Avian influenza virus,AIV）免疫层析快速检测技术,本研究以差速离心法纯化H9N2亚型AIV免疫BALB/c小鼠,将免疫小鼠脾细胞与骨髓瘤细胞SP2/0进行细胞融合和HAT选择性培养;以H9N2亚型AIV感染MDCK细胞建立异源免疫过氧化物酶单层细胞试验（IPMA）的单克隆抗体检测方法,通过对杂交瘤细胞的IPMA筛选和连续克隆化筛选鉴定抗H9N2亚型AIV中和性单克隆抗体;以胶体金标记HA单克隆抗体,配对HA单克隆抗体和羊抗小鼠IgG为检测线和质控线,制备H9N2亚型AIV快速检测试纸条,测定其特异性和敏感性。结果显示,获得了11株稳定分泌抗H9N2亚型AIV单克隆抗体的杂交瘤细胞,其单克隆抗体腹水IPMA效价在1.28×10^-4至2.56×10^-5之间。单克隆抗体3A2、5H6、6B8、7E10和9G12血凝抑制试验（HI）显示血凝抑制活性,其（HI）效价在6log2~9log2之间。单克隆抗体3A2、6B8和9G12在病毒中和试验中对H9N2亚型AIV有显著病毒中和活性,中和效价分别1∶6 400、1∶25 600和1∶25 600。Western blotting结果提示,该中和单克隆抗体识别HA蛋白线性抗原表位。利用配对单克隆抗体3A2和9G12研制的H9N2亚型AIV检测试纸条检测H9N2亚型AIV尿囊液的效价为9log2,灵敏度与经典血凝试验（HA）相当,与其他亚型AIV （H1、H3、H5、H7）,以及新城疫病毒和鸡传染性法氏囊病病毒等相关病毒均无交叉反应。本研究制备了具有病毒中和活性的抗H9N2亚型AIV单克隆抗体,并初步研制了H9N2亚型AIV检测试纸条,为H9N2亚型AIV新型疫苗研制和快速检测奠定良好的研究基础。     

犬瘟热病毒H蛋白的原核表达及免疫原性的初步鉴定

本研究旨在对犬瘟热病毒(CDV)疫苗株H基因进行克隆及原核表达,并对产物的免疫原性做初步鉴定。根据犬瘟热病毒参考株Ondetstepoort的H基因序列,去除信号肽序列并选取其主要抗原表位设计引物,用反转录—聚合酶链式反应(RT-PCR)扩增目的片段;产物克隆至表达载体pET28b并转化宿主菌Rosetta^TM,优化诱导表达条件,纯化目的蛋白,并进行SDS-PAGE鉴定、Western blotting分析及间接酶联免疫吸附试验(ELISA);并将纯化的H蛋白免疫小鼠,进行中和试验检测抗体效价。结果显示,PCR扩增得到1113 bp DNA片段;在37 ℃、1.0 mmol/L IPTG诱导条件下可获得较高水平的表达;经SDS-PAGE鉴定,表达的H蛋白分子质量为42.38 ku,与预期值相符;Western blotting显示,在42.38 ku出现特异性目的条带;ELISA结果显示,表达的H蛋白能被抗CDV抗体识别,但与正常血清未发生非特异性反应;中和试验结果表明,血清中和抗体效价约为2^－3.3。结果提示,H蛋白获得了正确表达,对CDV抗血清具有特异反应性,可作为实时检测动物机体免疫状况检测的候选抗原,为进一步研制犬瘟热抗体检测ELISA试剂盒和新型疫苗奠定基础。     

中华鳖对温和气单胞菌口服微球缓释疫苗的免疫应答

以中华鳖温和气单胞菌 (Aeromonas sobria,As) Z- 1株灭活全菌液 ,采用生物降解性高分子材料制成缓释微球疫苗 ,口服免疫中华鳖 ,测定血清中凝集抗体、血液中白细胞杀菌率以及对活菌攻击的免疫保护率。结果表明 ,中华鳖口服微球疫苗 ,其血清中凝集抗体效价和血液中白细胞杀菌百分率均可达到灭活菌液注射组相当的水平 (P>0 .0 5 ) ,显著高于对照组 (P<0 .0 1) ;微球疫苗口服组和灭活菌液注射组的免疫保护率分别为 94 .7%和 89.5 % ,两者差异不显著 (P>0 .0 5 ) ,而对照组小鼠 95 %死亡。采用可生物降解微球作为中华鳖气单胞菌口服疫苗的载体系统是可行的。     

Development of a water-in-oil-in-water adjuvant for foot-and-mouth disease vaccine based on ginseng stem-leaf saponins as an immune booster

There has been an increasing interest in finding new formulations that qualify as vaccine adjuvants, which must be safe, stable, and have the capacity to stimulate a strong immune response. In this study, a basic formulation of a water-in-oil-in-water (W/O/W) adjuvant CV13 was developed, and ginseng stem-leaf saponins (GSLS) were added as an immune booster into oil phase. The physicochemical properties of the adjuvant were tested. Furthermore, the immune activity and the adjuvant effects, as indicated by the foot-and-mouth disease virus (FMDV) antigen were evaluated. The results showed that CV13 was similar in appearance to ISA 206 and could package FMDV antigen into a stable W/O/W emulsion. The FMD vaccine prepared with CV13 alone or CV13 containing GSLS achieved pharmaceutical characteristics comparable to a vaccine prepared with ISA 206, moreover the structural stability of the CV 13 vaccine was found to be better. Mice that were immunized with the FMD vaccine prepared with CV13 containing GSLS presented a significantly higher LPBE antibody titer and splenocyte proliferation rate than those immunized with a vaccine prepared with CV13 alone (p < 0.05). In addition, there was no significant difference between the groups that were immunized with FMD vaccine prepared with CV13 containing GSLS and ISA206 in terms of cellular and humoral immune response. In this paper, CV13 containing GSLS shows excellent immunologic adjuvant effect in mice model, and this new adjuvant may provide a potential choice for FMD vaccine production in the future.